Fertility Testing in Europe: A Complete Guide to Tests, Results, and Next Steps

When pregnancy doesn't happen as quickly as expected, questions arise. Is everything working as it should? Should we get tested? Where do we start? Fertility testing can feel like a daunting step, but it is one of the most empowering things a couple can do when they're trying to conceive. Understanding your reproductive health gives you information, direction, and options—replacing uncertainty with clarity.

This comprehensive guide covers all aspects of fertility testing in Europe: what tests are available, what they measure, how to access testing through European healthcare systems or at home, what results mean, and what steps to consider based on your findings. Whether you're in Germany, France, the Netherlands, Spain, Italy, or any other European country, this guide will help you navigate the fertility testing landscape with confidence.

When Should You Consider Fertility Testing?

Most fertility specialists and European medical guidelines recommend seeking investigation after:

• 12 months of regular, unprotected intercourse if you are under 35
• 6 months if you are 35 or older
• Immediately or after 3–6 months if there are known risk factors such as irregular or absent periods, previous pelvic inflammatory disease (PID), prior cancer treatment, known endometriosis, or a history of undescended testicles in the male partner

However, many couples—particularly those who are older or who simply want information and reassurance—choose to begin basic testing sooner. This is entirely reasonable, and many tests are available without a referral or even without seeing a doctor at all.

The European Society of Human Reproduction and Embryology (ESHRE) recommends that both partners be investigated simultaneously, as male factor infertility contributes to approximately 40–50% of all cases. Testing only the female partner first is a common mistake that delays diagnosis.

Female Fertility Tests: What's Available

Female fertility testing covers several domains: hormonal function, ovarian reserve, the fallopian tubes, and the uterus. Here's a breakdown of the most important tests:

• Cycle Day 2–3 Hormone Panel (FSH, LH, Oestradiol): Blood tests taken in the early follicular phase (days 2–3 of the menstrual cycle) measure follicle-stimulating hormone (FSH), luteinising hormone (LH), and oestradiol (E2). Elevated FSH with elevated oestradiol on day 3 may indicate diminished ovarian reserve. LH:FSH ratio can be informative in PCOS diagnosis.
• Anti-Müllerian Hormone (AMH): AMH can be measured at any point in the cycle and is the best single marker of ovarian reserve—indicating how many eggs remain. AMH declines with age and can be low in women with diminished ovarian reserve. It can be elevated in PCOS. AMH testing is widely available across European fertility clinics.
• Progesterone (Day 21): A blood test taken approximately 7 days after expected ovulation (commonly day 21 in a 28-day cycle, but adjusted for cycle length) confirms whether ovulation has occurred. A level above 30 nmol/L is generally considered confirmatory of ovulation.
• Thyroid Function Tests (TSH, free T4): Thyroid dysfunction—both hypo- and hyperthyroidism—significantly affects fertility. TSH testing is often included in a standard fertility panel and should be a priority, as thyroid conditions are common and highly treatable.
• Prolactin: Elevated prolactin (hyperprolactinaemia) can suppress ovulation. It's sometimes elevated due to stress or timing of the blood draw, so an elevated result is typically repeated before acting on it.
• Pelvic Ultrasound: Transvaginal ultrasound provides detailed information about the ovaries (including antral follicle count, a marker of ovarian reserve), uterus (checking for fibroids, polyps, or structural abnormalities), and can identify features of PCOS or endometriosis.
• Hysterosalpingogram (HSG): An X-ray procedure using contrast dye injected through the cervix to visualise the uterine cavity and assess fallopian tube patency. It can identify blocked tubes, polyps, fibroids, or uterine abnormalities. Available in most European hospitals and fertility clinics.
• HyCoSy (Hysterosalpingo-Contrast Sonography): An ultrasound-based alternative to HSG that uses contrast to assess tubal patency. Less radiation exposure than HSG and increasingly preferred in many European centres.
• Laparoscopy: A surgical procedure offering direct visualisation of the pelvic organs. Recommended when endometriosis is suspected or when other investigations are inconclusive. Not typically a first-line investigation but provides the most definitive assessment of the pelvis.

Male Fertility Tests: Why They're Equally Important

Semen analysis is the cornerstone of male fertility testing and should be performed early in any fertility investigation. It is non-invasive, relatively inexpensive, and highly informative. ESHRE guidelines recommend semen analysis as a first-line test in all couples seeking fertility assessment.

A standard semen analysis evaluates:

• Sperm concentration (count): WHO reference values (2021 update) set the lower reference limit at 16 million sperm per millilitre (previously 15 million). Values below this are termed oligospermia.
• Total motility: The percentage of sperm that are moving. At least 42% total motility is the WHO lower reference limit. Progressive motility (sperm moving in a forward direction) should be ≥30%.
• Morphology: The percentage of sperm with a normal shape. Using the strict Kruger criteria, at least 4% normal forms is the reference value. Abnormal morphology is termed teratospermia.
• Volume and pH: Semen volume (reference ≥1.4 mL) and pH provide information about accessory gland function.
• Vitality: The percentage of live sperm, relevant when motility is very low.

Additional male fertility tests that may be recommended include:

• Sperm DNA Fragmentation Testing: Standard semen analysis doesn't assess the integrity of sperm DNA. High levels of fragmented DNA are associated with lower fertilisation rates, poor embryo quality, and recurrent miscarriage. DFI (DNA fragmentation index) testing is increasingly available across Europe.
• Hormone testing (FSH, LH, testosterone, prolactin): Indicated when sperm counts are very low (especially azoospermia—no sperm) to distinguish between testicular failure and hormonal causes.
• Scrotal/testicular ultrasound: Can identify varicocele (enlarged veins in the scrotum, which affect sperm production in a significant minority of men with infertility) and structural abnormalities.
• Genetic testing: Recommended for men with very low or absent sperm counts. Y-chromosome microdeletion testing and karyotyping can identify genetic causes of male infertility.

At-Home Fertility Testing: What's Available Across Europe

The at-home fertility testing market has expanded dramatically across Europe in recent years, making it easier than ever to begin your fertility assessment in the privacy and comfort of your own home. These tests represent a useful starting point—though they don't replace comprehensive clinical testing.

Available at-home tests include:

• Ovulation predictor kits (OPKs): Detect the LH surge that precedes ovulation. Available across Europe in pharmacies and online. Digital versions quantify LH levels over multiple days, giving a clearer picture of the fertile window. Some newer devices also track oestrogen to identify the full fertile window.
• At-home hormone testing: Finger-prick blood tests that can measure FSH, LH, AMH, oestradiol, and thyroid hormones, with samples sent to a certified laboratory. Several European companies offer these services, with results delivered digitally within days.
• At-home sperm testing: Devices that can assess sperm concentration and motility using a smartphone or dedicated reader. While not as comprehensive as a full clinical semen analysis, they provide a useful initial indication. WHO-validated home sperm tests are available across European markets.
• Early pregnancy tests (hCG): High-sensitivity tests that can detect pregnancy hormones earlier than standard pharmacy tests.

At-home testing works best as a starting point or for monitoring purposes. Abnormal results should always be followed up with clinical testing and professional guidance.

Navigating Fertility Testing Across European Healthcare Systems

Access to fertility testing and treatment varies significantly across European countries, shaped by national healthcare systems, reimbursement policies, and cultural attitudes toward assisted reproduction.

• Germany: Statutory health insurers (GKV) cover basic fertility investigations and contribute to up to three IVF cycles for married couples, covering 50% of costs. Private fertility clinics offer comprehensive testing without waiting times.
• France: France has one of Europe's most generous fertility treatment systems. Social security covers fertility investigations and up to six IVF attempts for women under 43. Both heterosexual and same-sex female couples are eligible.
• Netherlands: Basic fertility investigations are covered by health insurance. IVF is partially reimbursed, typically up to three cycles, though criteria and co-payments vary by insurer.
• Spain: Private fertility clinics are world-renowned, with Spain being the largest IVF destination in Europe. Public health system coverage varies by region (comunidad autónoma). Diagnostic testing is generally available through the public system.
• Italy: Public system coverage for fertility treatment is limited and varies by region. Private clinics are widely used. Testing for male factor infertility is readily available.
• Scandinavia: Denmark, Sweden, Norway, and Finland all offer relatively generous public fertility treatment coverage, though criteria vary. Denmark in particular has high usage rates of fertility treatment.

For couples who want comprehensive, timely fertility testing regardless of public system capacity, private fertility clinics across Europe offer complete diagnostic packages—often at competitive prices compared to the UK or US.

Understanding Your Results: What Do the Numbers Mean?

Receiving fertility test results can be overwhelming. Here's a framework for interpreting the most common findings:

• Normal results: Don't mean conception will happen immediately or easily, but they're reassuring and may point toward timing, lifestyle, or unexplained infertility as the next focus.
• Elevated FSH or low AMH: Suggests diminished ovarian reserve. Doesn't mean conception is impossible, but time is important. Consider seeking specialist advice promptly, especially if over 35.
• Abnormal semen analysis: Mildly abnormal results may improve with lifestyle changes and supplementation over 3 months (the time for sperm production). Significantly abnormal results warrant specialist assessment and possibly further testing.
• Ovulation confirmed: A progesterone result above 30 nmol/L is reassuring. If ovulation isn't occurring, this is an important finding that's often very treatable.
• Blocked tubes: If one tube is blocked, the other may be sufficient for natural conception. Bilateral tubal blockage typically requires IVF to achieve pregnancy.
• Unexplained infertility: When all standard tests are normal but conception hasn't occurred. This is actually quite common and doesn't mean nothing is wrong—it may simply mean the cause hasn't been identified yet. Further investigation or moving to treatment is appropriate.

Frequently Asked Questions About Fertility Testing in Europe

Q: Can I do fertility testing before we start trying to conceive?
A: Absolutely. Pre-conception fertility testing is increasingly popular in Europe and can identify potential issues before they cause delays in conception. AMH testing, semen analysis, and thyroid function testing are all reasonable to do proactively.

Q: How accurate are at-home fertility tests?
A: Ovulation predictor kits are highly accurate for detecting the LH surge. At-home sperm tests and finger-prick hormone tests have good accuracy for initial screening, though clinical laboratory testing provides more comprehensive results. Any concerning at-home results should be followed up clinically.

Q: Does sperm analysis have to be done at a clinic?
A: A full semen analysis (including morphology assessment) requires a clinical laboratory. However, at-home sperm concentration and motility tests can provide a useful initial picture. If at-home results are concerning, a formal semen analysis at a clinic is the next step.

Q: What is the AMH test and why is it important?
A: AMH (Anti-Müllerian Hormone) measures ovarian reserve—effectively the quantity of eggs remaining. It's particularly useful because it can be measured at any time in the cycle and gives a good indication of how the ovaries will respond to stimulation. Low AMH suggests diminished reserve and may influence the urgency of family planning decisions.

Q: Is fertility testing covered by European health insurance?
A: Coverage varies significantly by country and insurer. Basic investigations (blood tests, semen analysis) are generally covered in most European public health systems. Specialist tests (AMH, HSG, laparoscopy) may require referral. Treatment coverage varies enormously—France is particularly generous, while countries like Italy and Germany have more limited public coverage.

Q: Should both partners be tested at the same time?
A: Yes—this is strongly recommended by ESHRE and all major fertility guidelines. Male factor contributes to nearly half of all infertility cases, and investigating only one partner first is inefficient and can delay diagnosis by months.

Q: Can fertility tests tell me if I will definitely get pregnant?
A: No test can guarantee pregnancy. Tests identify whether specific factors that can impair fertility are present—they don't measure all aspects of fertility or predict outcomes with certainty. Even couples with normal results may experience delays; even those with abnormal results may conceive naturally or with treatment.

Q: What is sperm DNA fragmentation testing and who needs it?
A: Sperm DNA fragmentation measures the integrity of the genetic material within sperm. High fragmentation rates are associated with recurrent miscarriage, failed IVF cycles, and poor embryo quality even when standard semen analysis is normal. It's particularly recommended for couples with unexplained infertility or recurrent pregnancy loss.

Q: How long does it take to get fertility test results in Europe?
A: Blood test results are typically available within 24–72 hours. Semen analysis results are usually available within a few days. Imaging (ultrasound, HSG) results are typically discussed immediately or within a few days. At-home hormone test kits (finger-prick) usually take 3–5 days once the sample reaches the lab.

Q: What should we do if our results are normal but we're still not conceiving?
A: Normal results with ongoing difficulty conceiving is termed "unexplained infertility." This is actually relatively common. Options include more detailed investigation (sperm DNA fragmentation, immunological testing, more detailed imaging), lifestyle optimisation, or moving to treatment (IUI or IVF). A fertility specialist can guide appropriate next steps.